

Shavenbaby and Yorkie mediate Hippo signaling to protect adult stem cells from apoptosis

Jérôme Bohère¹, Alexandra Mancheno-Ferris¹, Kohsuke Akino², Yuya Yamabe², Sachi Inagaki³, Hélène Chanut-Delalande¹, Serge Plaza⁴, Yuji Kageyama^{2,3}, Dani Osman⁵, Cédric Polesello^{1*} & François Payre^{1*}

¹ Centre de Biologie du Développement (CBD), Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, Bat 4R3, 118 route de Narbonne, F-31062 Toulouse, France

² Department of Biology, Graduate School of Science, Kobe 657-8501, Japan

³ Biosignal Research Center, Kobe University, 1-1 Rokko-dai, Nada, Kobe 657-8501, Japan

⁴ Present Address: Laboratoire de Recherche en Sciences Végétales (LSRV), CNRS, UPS, 24 chemin de Borde Rouge, Auzeville, 31326 Castanet-Tolosan, France

⁵ Faculty of Sciences III and Azm Center for Research in Biotechnology and its Applications, LBA3B, EDST, Lebanese University, 1300, Tripoli, Lebanon

* Correspondence and requests for materials should be addressed to C.P. or F.P.

(email: cedric.polesello@univ-tlse3.fr, francois.payre@univ-tlse3.fr)

Abstract

To compensate for accumulating damages and cell death, adult homeostasis (e.g., body fluids and secretion) requires organ regeneration, operated by long-lived stem cells. How stem cells can survive throughout the animal life yet remains poorly understood. Here we show that the transcription factor Shavenbaby (Svb, OvoL in vertebrates) is expressed in renal/nephric stem cells (RNSCs) of *Drosophila* and required for their maintenance during adulthood. As recently shown in embryos, Svb function in adult RNSCs further needs a post-translational processing mediated by Polished rice (Pri) smORF peptides and impairing Svb function leads to RNSC apoptosis. We show that Svb interacts both genetically and physically with Yorkie (YAP/TAZ in vertebrates), a nuclear effector of the Hippo pathway, to activate the expression of the inhibitor of apoptosis *DIAP1*. These data therefore identify Svb as a novel nuclear effector in the Hippo pathway, critical for the survival of adult somatic stem cells.

Keywords

Stem cells, OVOL/Shavenbaby, smORF peptides, Hippo pathway, apoptosis, Renal system, Malpighian tubules, *Drosophila*.

The family of OvoL/Ovo/Shavenbaby (Svb) transcription factors has been strongly conserved across evolution¹ and is characteristic of animal species. Initially discovered in flies for a dual function in the development of epidermal derivatives (Svb) and of the germline (Ovo)^{2,3}, mammalian orthologs (OvoL1-3) have soon been identified⁴⁻⁶. *OvoL/svb* genes produce several protein isoforms and the existence of three partially redundant paralogs in mammals complicates their genetic analysis. There is a single gene in *Drosophila*, which expresses germline- (*ovo*) and somatic-specific (*svb*) transcripts from different promoters. Previous work has well-established the role of Svb in the development of embryonic epidermal tissues³, where it triggers a tridimensional cell shape remodeling for the formation of actin-rich apical extensions, called trichomes. *Svb* expression is driven by a large array of *cis*-regulatory regions, which have become a fruitful paradigm for elucidating the function^{7,8} and evolution⁹⁻¹¹ of developmental enhancers. Svb enhancers directly integrate multiple inputs from upstream regulatory pathways⁷ and often drive similar patterns, all together conferring robustness to epidermal development in the face of varying environmental conditions and/or genetic backgrounds^{7,8}. During embryogenesis, the Svb transcription factor directly activates a battery of >150 target genes¹²⁻¹⁴ collectively responsible for actin and extra-cellular-matrix reorganization that underlie trichome formation¹⁵. Recent studies have unraveled a tight control of Svb transcriptional properties, in response to Polished rice (Pri, also known as Tarsal-less) peptides, which belongs to a novel family of peptides encoded from small open reading frames (smORF) hidden within apparently long noncoding RNAs¹⁶. Svb is first translated as a long-sized protein that acts as a repressor (Svb^{REP})¹⁷. Pri smORF peptides then induce a proteolytic processing of Svb^{REP} leading to the degradation of its N-terminal region and releasing a shorter activator form, Svb^{ACT}¹⁷. Further work has demonstrated that *pri* expression is directly regulated by periodic pulses of steroid hormones¹⁸, allowing a functional connection between hard-wired genetic regulatory networks (*svb* expression) and

systemic hormonal control (mediated by *pri*) for a proper spatio-temporal control of epidermal cell morphogenesis¹⁶.

Recent studies suggest that OvoL/Svb factors display broader functions throughout epithelial tissues in both normal and various pathological situations. Molecular profiling of human tumors has revealed that OvoL deregulation is a feature of many carcinomas, directly linked to the metastatic potential of morbid cancers¹⁹⁻²³, including kidney²⁴. OvoL factors have been proposed^{25, 26} to counteract a conserved core of regulators composed of Snail/Slug and Zeb1-2 transcription factors, as well as the micro RNA *mir200*, well known to promote epithelial-mesenchymal transition (EMT)²⁷. The activity of OvoL might help stabilizing a hybrid E/M phenotype^{21, 25}, providing many advantages for both tumors and normal stem cells²⁸. Indeed, recent data show that, like adult somatic stem cells, the most aggressive tumors often display a hybrid phenotype between mesenchymal and epithelial states²⁷, and the expression of specific OvoL isoforms can annihilate the metastatic potential of mammary tumors^{29,19}. In addition, OvoL/Svb factors have been linked to the control of various progenitors/stem cells, from basal invertebrates³⁰ to mammals³¹⁻³³. Therefore, whereas a large body of evidence supports a key role for OvoL/Svb in the behavior of somatic stem cells, a functional investigation of their mode of action *in vivo* remains to be undertaken.

Here we built on the knowledge and tools accumulated for the study of Svb function in flies to investigate its putative contribution to the behavior of somatic stem cells in the adult. We show that in the Malpighian tubules, which ensure essential renal functions in insects^{34, 35}, *svb* is specifically expressed in the adult renal and nephric stem cells (RNSCs, see Fig. 1a). We further find that a main function of Svb in the kidney is to protect RNSCs from apoptosis by controlling the expression of the inhibitor of apoptosis, *DIAP1*, in interaction with Yorkie, a nuclear effector of the Hippo pathway.

Results and Discussion

svb is expressed in Renal Nephric Stem Cells and controls their maintenance

To assay whether *svb* might be expressed in the adult, we tested large genomic reporter constructs that cover each of the seven enhancers contributing to *svb* expression. We found that one enhancer⁹, *svb*^{E10}, drove specific expression in tiny cells of the Malpighian tubules (Supplementary Fig. 1a, b).

Adult Malpighian tubules are mainly composed of two types of differentiated cells³⁵ (Fig. 1a). The principal cells -characterized by the homeodomain Cut protein- express the vacuolar-ATPase (V-ATPase) that establishes an H⁺ electrochemical potential promoting *trans*-epithelial secretion of Na⁺ and K⁺³⁴. The second main population of Malpighian tubules are termed stellate cells, featured by the expression of the Teashirt transcription factor, and that regulate the transport of Cl⁻ and water³⁴. While both principal and stellate cells display large-sized polyploid nuclei, a third population of tiny diploid cells³⁶ are located in the lower tubules and correspond to RNSCs^{34, 35, 37} (Fig. 1a). RNSCs derive from a subpopulation of intestinal stem cell precursors that colonize Malpighian tubules during post-embryonic development^{37, 38}. RNSCs are characterized by the expression of Escargot, a transcription factor of the Snail/SLUG family that is also expressed in intestinal stem cells (ISCs³⁹) where it acts to prevent ISC differentiation^{40, 41}. Co-localization with an *esg*-LacZ reporter confirmed that the *svb*^{E10} enhancer was active in RNSCs (Fig. 1b and Supplementary Fig. 1b). To define the minimal region of *svb* responsible for the expression in RNSCs, we assayed a collection of overlapping constructs⁷. This identified two independent elements, the *svb*^{E3N} and *svb*^{E6} enhancers^{7, 9}, which despite having distinct activities during embryogenesis^{9, 42} drove similar expression in adult RNSCs (Supplementary Fig. 1c).

Having established that two enhancers drive specific expression of *svb* in the adult stem cells of the renal system, we next assayed consequences of depleting *svb* function in RNSCs. We used a well-controlled genetic system, hereafter referred to as *esg^{ts}*, ensuring RNAi-mediated gene depletion, specifically in the stem cells and only at the adult stage⁴³. We also developed an image analysis pipeline, allowing automated quantification of the whole population of RNSCs (see methods). In control conditions, the number of *esg*-positive RNSCs remains stable after adult hatching, with approx. 350 cells *per* tubules (Fig. 1c,d). We only noticed a weak reduction of RNSCs (300 cells) after one month. In contrast, *esg^{ts}*-driven RNAi depletion of *svb* led to a dramatic loss of RNSCs, which were completely absent after 32 days of treatment (Fig. 1c,d). The effects of *svb* depletion were already strong following 8 days of treatment, with a two-fold reduction in the number of RNSCs. Similar results were observed when using an independent driver of RNSCs (*Dome-meso-gal4*) to direct RNAi-mediated knockdown of *svb* (Supplementary Fig. 1d,e). The loss of RNSCs upon *svb* depletion was also confirmed by staining against Hindsight, another transcription factor specific of RNSCs within Malpighian tubules (Supplementary Fig. 1d,e). Finally, the key role of *svb* in the maintenance of adult RNSCs was further demonstrated by results from genetic mosaics, showing that *svb*-null mutant cells⁴⁴ were unable to maintain RNSCs (Fig. 1e).

Taken together, these data thus reveal that *svb* is specifically expressed in RNSCs and critically required for the maintenance of the adult stem cell compartment.

Svb processing is essential for its activity in Renal Nephric Stem Cells

In the epidermis, Svb activity relies on a proteolytic processing that causes a switch from a repressor to an activator form. This processing is gated by Pri regulatory peptides, which bind to and activate the Ubr3 ubiquitin E3-ligase that, in turn, triggers a limited degradation

operated by the proteasome⁴⁵ (Fig. 2a). Thereby, *pri* mediates a systemic control of Svb maturation since the expression of *pri* is directly regulated by the ecdysone receptor (EcR)¹⁸. To assess whether the function of Svb in Malpighian tubules also required its proteolytic maturation, we investigated a putative function of *pri* and *ubr3* in RNSCs. We screened a collection of *pri* reporter lines^{18, 46} and identified two *cis*-regulatory regions driving expression in RNSCs (Fig. 2b and Supplementary Fig. 2a,b). Consistently with the expression of *pri* in RNSCs, *pri* depletion almost fully eliminated RNSCs upon 8 days of RNAi treatment (Fig. 2d and Supplementary Fig. 2c). In addition, a dominant negative form of the Ecdysone Receptor (EcRDN) that abolishes *pri* expression during both embryonic and post-embryonic development¹⁸ was sufficient to reduce the number of stem cells when specifically expressed in adult RNSCs (Fig. 2d). Furthermore, we found that *ubr3* was also required for RNSC maintenance, as deduced from results of RNAi-mediated depletion and genetic nullification⁴⁵ of *ubr3* activity (Fig. 2c,d). Finally, the expression of OvoA that behaves as a constitutive repressor isoform of Svb^{17, 44, 47} mimicked the effects observed in *svb* loss of function conditions (Fig. 2d). Reciprocally, the expression of OvoB that acts as a constitutive activator isoform of Svb^{17, 44, 47} was sufficient to rescue the lack of *ubr3* function (Fig. 2d and Supplementary Fig. 2c), demonstrating that Svb function in RNSCs relies on its matured transcription activator form.

These results provide compelling evidence that the whole regulatory machinery discovered for its role in the development of epidermal cells^{17, 18, 45} is also at work in adult RNSCs. We therefore concluded that the post-translational maturation of the Svb transcription factor is essential for the maintenance of RNSCs.

Svb protects Renal Nephric Stem Cells from apoptosis

The loss of RNSCs observed following the lack of *svb* function or maturation could theoretically result from at least three different causes: i) lack of proliferation, ii) precocious differentiation, or iii) increased cell death. Consistent with the quiescent behavior of RNSCs, we observed a very low frequency of RNSC mitosis in controls, as deduced from staining with the mitotic marker Histone3-P (Supplementary Fig. 3a) and as previously noticed³⁷. Therefore, even a complete block of stem cell division cannot account for the disappearance of RNSCs observed in the absence of *svb*. Using the lineage-tracing system called ReDDM that has been recently developed for intestinal stem cells⁴⁸, we next investigated a putative influence of *svb* on RNSC differentiation. Based on differences in the stability of two fluorescent proteins, ReDDM allows marking renal progenitors that express both mCD8::GFP and H2B::RFP, while their progeny only maintain the very stable H2B::RFP⁴⁸. In control conditions, we detected very rare H2B::RFP progeny (Fig. 3a) confirming low cell renewal in Malpighian tubules³⁷. Recent work has shown that the expression of *mir-8* (the *Drosophila* homolog of *mir-200* in vertebrates) downregulate the expression of EMT-inducing factors Escargot and Zfh1 (the homolog of Zeb1), triggering a strong burst of stem cell differentiation in the intestine⁴⁸. Similarly, we found that *mir-8* expression in RNSCs forced *esg*⁺ cells to differentiate and only rare RNSCs persisted after 8 days of treatment (Fig. 3a). Upon *mir-8* expression, the progeny (H2B::RFP-positive, GFP-negative cells) of RNSCs present in lower tubules also expressed Alkaline Phosphatase 4, a marker of a subset of differentiated principal cells⁴⁹ confirming that the depletion of RNSCs upon *mir-8* overexpression was caused by their premature differentiation (Supplementary Fig. 3b). In contrast, no modification of the progenitors/progeny ratio was observed in *svb*-RNAi conditions when compared to controls, showing that *svb* depletion does not trigger RNSC differentiation (Fig. 3a). Finally, we tested whether *svb*-depleted RNSCs were lost because they underwent apoptosis. Since apoptotic

figures are difficult to observe in the digestive track⁵⁰ including the Malpighian tubules, we assayed consequences of blocking programmed cell death by expressing the viral caspase inhibitor p35⁵¹. Although the expression of p35 had no detectable effect by itself on RNSCs, it significantly rescued the number of RNSCs when *svb* was depleted (Fig. 3c and see below). Taken together, these data show that the loss of RNSCs observed upon *svb* loss of function is primarily due to stem cell death, indicating that a main role of Svb is to protect adult stem cells from undergoing apoptosis.

Svb acts downstream of Hippo

During epidermal development, *svb* is expressed in post-mitotic cells where it acts as a terminal differentiation factor that controls cell shape remodeling^{15, 52}. We noticed that RNSCs lacking *svb* displayed a reduced size, as well as an altered morphology (Fig. 3b). One could speculate that these defects in cell shape might stress RNSCs and thus induce apoptosis. Indeed, the Hippo pathway^{53, 54} is a key sensor of mechanical stress renowned to induce apoptosis following cytoskeleton modifications^{55, 56}. The core Hippo complex is composed of two kinases, Hippo (Hpo) and Warts and two scaffolding proteins, Salvador and Mob As Tumor Suppressor^{53, 54}. Activation of Hippo leads to the phosphorylation of the co-transcription factor Yorkie (Yki) that results in Yki nuclear exclusion/degradation, preventing its positive action on the transcription of target genes such as *DIAP1* and *bantam*^{53, 54}. Previous work has shown that the Hippo pathway is a key regulator of the *Drosophila* gut homeostasis, controlling survival and proliferation of stem cells for tissue regeneration^{57, 58}. Consistently, we found that the activation of Hpo induced a strong reduction in the number of RNSCs. However, co-expression of OvoB, the constitutive activator isoform of Svb, together with Hpo was sufficient to rescue the loss of RNSCs (Fig. 4a). These results therefore

demonstrated that if Svb and Hpo interact for the homeostasis of RNSCs, the loss of RNSCs observed upon *svb* knockdown is not due to the activation of the Hippo pathway, since Svb is instead acting downstream Hpo. In contrast, overexpression of Yki (mimicking a loss of Hippo signaling⁵⁹) induced a strong increase in *esg*⁺ renal cells, which displayed abnormal tumor-like morphology when compared to wild-type RNSCs (Fig. 4a). Unexpectedly, this increase in the number of renal stem cells was entirely suppressed upon *svb* depletion, or expression of the constitutive repressor OvoA (Fig. 4a and Supplementary Fig. 3f). Quantification indicated that *esg*⁺ cells overexpressing Yki were even more sensitive to *svb* loss-of-function than otherwise normal RNSCs (Fig. 4a), a result well in line with the extra-resistance of intestinal stem cells to apoptosis when compared to tumorous stem-like cells⁵⁰. Hence, the function of Yki in RNSCs requires Svb, suggesting that Svb was acting either downstream or in parallel with this nuclear effector of Hippo. Several lines of evidence ruled out the former and validated the latter hypothesis. First, knocking down Yki also led to RNSC loss (Supplementary Fig. 3c). Expression of the Svb constitutive activator (OvoB) was nevertheless not able to rescue RNSC survival in the absence of Yki (as opposed to the overexpression of Hpo, Fig. 4a), showing that Svb requires Yki activity for RNSC maintenance (Fig. 4a and Supplementary Fig. 3c). Second, although Yki is sufficient to induce *DIAP1* expression⁶⁰ (and see below), Yki was not able to rescue the lack of Svb while DIAP1 alone did (Fig. 4a). Indeed, we found that DIAP1 was sufficient to compensate for *svb*-depletion (Fig. 4a and Supplementary Fig. 3f). In sum, while both Svb and Yki are required for RNSC maintenance, re-expression of Yki is not sufficient to rescue the loss of *svb* function. Reciprocally, Svb is not sufficient to rescue a proper RNSC compartment in the absence of Yki, showing that Svb and Yki act in parallel for the survival of adult stem cells. We thus concluded that Svb acts downstream of Hippo cytoplasmic core components and, together with Yki, both nuclear factors are required to protect RNSCs from apoptosis.

Svb as a novel nuclear effector of the Hippo pathway

Having established that Svb and Yki genetically interact, we wondered whether the two proteins might interact to control the expression of common target genes, *e.g.*, *DIAP1*. Yki is unable to bind DNA by itself and need to associate to sequence-specific-transcription factors⁵⁴. Interestingly, Yki contains two WW protein domains shown to mediate interaction with partners bearing PPxY motifs (such as Wts⁶⁰, Wbp2⁶¹ and Mad⁵⁹), and we detected two PPxY motifs within the Svb protein, at position 523 (PPFY) and 881 (PPSY). Co-immunoprecipitation assays showed that Svb bound to the wild type form of Yki, while the mutation of Yki WW motifs was sufficient to abrogate the interaction with Svb (Fig. 4c). A second piece of evidence emerged from the comparison of chromatin immuno-precipitation (ChIP-seq) datasets between Svb¹⁴ and Yki⁶². We found that Svb and Yki share 836 common genomic binding sites (Supplementary Fig. 4a) and statistical tests established the significance of this overlap (Supplementary Fig. 4b). Interestingly, co-binding of Yki was rare for the direct target genes of Svb identified in the epidermis¹²⁻¹⁴, as illustrated by *shavenoid* or *dusky-like* that both lack Yki binding (Supplementary Fig. 4d,d'). In contrast, Svb was often bound to known Yki target genes, such as *bantam*, *fat*, *piwi* or *nanos*⁶³ (Supplementary Fig. 4c,c'). ChIP-seq also revealed that Svb and Yki bound to a same region of *DIAP1*, within an enhancer driving specific expression in adult intestinal stem cells⁶⁴ (Fig. 4b). We therefore tested if Svb might regulate *DIAP1* expression. Although very weak in control conditions, expression of *DIAP1-LacZ* was strongly enhanced upon Yki overexpression. This induction was completely antagonized by OvoA (Fig. 4d). Similar results were obtained with the isolated *DIAP1* enhancer (*DIAP1-4.3-GFP*) containing the binding sites of Yki and Svb, the expression of which was again enhanced by Yki overexpression and abrogated upon counteracting Svb activity (Fig. 4e). These data thus strengthen the conclusion that Svb and

251 Yki functionally interact in RNSCs to prevent apoptosis, at least in part through promoting
 252 *DIAP1* expression.

253 One important question was whether the interaction between Svb and the Hippo pathway also
 254 took place in other tissues. The function of Hippo has been initially described in imaginal
 255 discs, which give rise to most adult tissues⁶⁵ and Yki overexpression promotes cell
 256 proliferation in both wing and eye discs⁶⁰. We tested Svb/Yki genetic interactions in the wing
 257 using *collier-Gal4* that drives expression in the medial (L3-L4) intervein region. *Yki* over-
 258 expression resulted in the expansion of this region due to tissue overgrowth (Supplementary
 259 Fig. 3d). In contrast, *OvoA* leads to both a reduction of the L3-L4 region and the absence of
 260 epidermal trichomes. As in RNSCs, *OvoA* was epistatic to Yki, since the wing region
 261 expressing both *yki* and *ovoA* was smaller than in controls and lacked trichomes
 262 (Supplementary Fig. 3d). In the eye, overexpression of Yki using the *GMR-Gal4* driver
 263 promoted extra cell proliferation resulting in an increased eye size. Similar results were
 264 obtained following *pri* overexpression, and co-expressing *pri* and *yki* resulted in a synergistic
 265 eye growth (Supplementary Fig. 3e). Northern blotting of RNAs extracted from adult heads
 266 revealed that *DIAP1* mRNA levels were increased following *pri* overexpression
 267 (Supplementary Fig. 4e), while there was no effect on *yki* or *cycE* mRNA.

268 We interpret these results to imply that Svb functionally interacts with Yorkie, both in adult
 269 stem cells and in developing tissues, to regulate a subset of transcriptional targets of the
 270 Hippo pathway, including the activation of *DIAP1* expression.

Conclusions

Our results show that Shavenbaby is expressed and required for the maintenance of adult renal stem cells (RNSCs) in flies, supporting the conclusion that the OvoL/Svb family of transcription factors plays a key and evolutionarily-conserved role in the behavior of progenitors-stem cells.

The role of Svb in adult stem cell maintenance in flies requires both a fine control of its expression and of its transcriptional activity. Svb expression in RNSCs involves at least two separable enhancers, driving similar expression patterns. Svb was one the first cases to reveal the functional importance of apparently redundant (or shadow) enhancers in the phenotypic robustness of developmental networks⁸. Our data suggest that a similar *cis*-regulatory architecture is also underlying the control of adult stem cells.

RNSCs maintenance further requires a proper post-translational maturation of the Svb protein, in the response to Pri smORF peptides. During both embryonic¹⁷ and post-embryonic development^{18, 45}, the main role of Pri peptides is to provide a temporal control of Svb activity, conveying systemic steroid signaling¹⁸. It is therefore possible that Pri smORF peptides also connect genetic networks to hormonal control for the regulation of adult stem cells. Recent work has shown that various smORF peptides contribute to the regulation of developmental pathways, muscle formation and physiology, etc...^{16, 66, 67}, and our findings extend their influence to the control of adult stem cells. It has been proposed that the emerging field of smORF peptides may open novel therapeutic strategies, for example peptidomimetic drugs, which might also be of interest for regenerative medicine.

Complementary data establish that a main function of Svb in adult stem cells is mediated by a functional interplay with the Hippo pathway, well established for its roles in the control of adult stem cells^{53, 57, 58, 68}. Our results indicate that Svb behaves as a novel nuclear effector of

Hippo, relying on a direct interaction with Yorkie in order to protect stem cells from apoptosis, at least in part through the regulation of *DIAP1* expression. Analysis of genome-wide binding events further suggests that the Svb/Yki interaction is involved in the control of a broader set of Hippo-regulated genes, including during development. Since both Pri and Ubr3 are also essential for the survival of adult stem cells, it is interesting to note that Ubr3 protects the DIAP1 protein from degradation⁶⁹, and direct binding of Ubr3 on the activated form of DIAP1 is elicited in the presence of Pri peptides⁴⁵. Therefore, in addition to the control of *DIAP1* expression (*via* Svb), Ubr3 and Pri could also stabilize the DIAP1 protein to protect stem cells from apoptosis. Although initially restricted to TEAD transcription factors, the number of Yorkie (YAP/TAZ) nuclear partner is rapidly growing⁵⁴. Recent work has shown a direct interaction of YAP/TAZ with the Snail/Slug pro-EMT factors in the control of stem cell renewal and differentiation⁷⁰. As previously reported for intestinal stem cells^{40, 41, 48}, pro-EMT regulators are also required for preventing premature differentiation of renal stem cells. While pro-EMT and OvoL factors are often viewed as antagonistic factors^{19, 21, 25}, *in vivo* studies in *Drosophila* stem cells show that they both contribute to their maintenance, Svb/Yki preventing their apoptosis and EMT factors their differentiation. Many studies having implicated the Hippo pathway, pro-EMT and OvoL/Svb factors in various tumors, new insights into their functional interactions in adult stem cells may provide additional knowledge directly relevant to understand their connections in human cancers.

Methods

Fly stocks. The following *Drosophila* stocks were used in this study: *tsh-LacZ* (BL#11370), *esg-lacZ* (BL#10359), *esg-Gal4*, *UAS-GFP*; *tubulin-Gal80^{ts}/SM6-TM6B*⁴³ (B. Edgar), *yw*, *hsFLP*, *tubulin-Gal80 FRT19A*; *UAS-mcd8::GFP/Cyo*; *tubulin-Gal4/TM6 Tb* (N. Tapon), *esg-Gal4, UAS-mcd8::GFP/Cyo*; *UAS-H2B::RFP*, *tubulin-Gal80^{ts}/TM2*⁴⁸ (M. Dominguez), *col-Gal4*, *UAS-mcd8::GFP/Cyo* and *domeMeso-Gal4* (M. Crozatier), *GMR-Gal4 /Cyo* (BL#9146), *tal-Gal4/ TM3 Sb* (J.P. Couso), *svb^E-GFP*, *svb^{E10}-lacZ*, *svb^{E3N}-lacZ*, *svb^{E6}-lacZ* (D. Stern), *svb^{E3N}-GFP* (this work), *svb^{R9}*, *FRT19A/ FMO*⁴⁴, *ubr3^B FRT19A/ FMO*⁴⁵ (H. Bellen), *Diap1-lacZ* (BL#12093) , *UAS-svb RNAi* (VDRC #v40316), *UAS-ubr3 RNAi* (VRDC #22901), *UAS-yki RNAi* (VDRC #KK104523), *UAS-pri RNAi* (J.P. Couso), *UAS-OvoA*⁴⁴, *UAS-OvoB*⁴⁴, *UAS-EcRDN* (BL#9449), *UAS-mir8* (S.M. Cohen), *UAS-p35* (B. Monier), *UAS-hpo/CyO* (N. Tapon), *UAS-yki/TM3 Sb* (D.J. Pan), *UAS-DIAP1* (N. Tapon), *UAS-pri/CyO* (J.P. Couso).

Flies were cultured (unless otherwise noted) at 25°C, using standard cornmeal food (*per* liter: 17g inactivated yeast powder, 80g corn flour, 9g agar, 45g white sugar and 17ml of Moldex). Similar results were also observed using a richer medium (same composition except 45g of yeast powder). Female adult flies were used in all analyses throughout the study and placed on fly food supplemented with fresh yeast, which was changed every two days. Conditional expression in RNSCs was achieved by maintaining *tub-Gal80^{ts}* expressing flies at 18°C, until adulthood. Eclosed females aged for 3- to 4-days were shifted to 29°C for induction of gene expression and were kept at 29°C for the indicated period of time (in most cases 8 days). Virgin females bearing *svb^{R9}*, *svb^{PL107}* or *ubr3^B* mutations^{44, 45} over FM0 balancers were mated with males of the following genotype: *yw*, *hs-FLP*, *tub-Gal80*, *FRT19A*; *UAS::mcd8-GFP*; *tub-Gal4/TM6, Tb*. Females of the correct phenotype (no *B* and no *Tb*) were heat shocked for 1h at 37°C. Flies were transferred on fresh food every two days and dissected at the indicated

time. Detailed information about the full genotype of each *Drosophila* stock is given in the genotype section below.

Histology. Tissues were dissected in 1X PBS, fixed in 4% formaldehyde in PBS for 15 min at room temperature, washed for 5 min in PBS containing 0.1% Triton X-100 (PBT) and fixed again during 20 min. Following a 5 min wash (PBT 0.1), tissues were then blocked for 30 minutes in PBT containing 1% BSA. Primary antibodies were incubated overnight at 4°C. Anti-β-Galactosidase (Cappel) antibody was used at 1/1000, Cut (DSHB) and GFP antibodies at 1/200, and phospho-HistoneH3 (Upstate) and Disc-large (DSHB) antibodies at 1/500. AlexaFluor-488 or 555 secondary antibodies (Molecular Probes) were incubated for 2 hrs at room temperature at 1/500. After washes, tissues were mounted in Vectashield (Vector). For X-gal staining, adult tissues were dissected in 1X PBS, fixed in 1% glutaraldehyde in PBS for 15 min at room temperature and washed in PBS. The staining solution was warmed up at 37°C for 10 min plus 10 other min after addition of 8% X-Gal (5-bromo-4-chloro-3-indoyl-β-D-Galactopyranoside). The X-Gal solution used to reveal the β-Galactosidase activity was: 10mM NaH₂PO₄.H₂O/ NA₂HPO₄.2H₂O (pH=7.2), 150mM NaCl, 1mM MgCl₂.6H₂O, 3.1mM K₄ (FeII(CN)₆), 3.1mM K₃ (FeIII(CN)₆), 0.3 % Triton X-100. Bright-field pictures were acquired using a Nikon eclipse 90i microscope.

Microscopy, image and statistical analysis. Images of whole Malpighian tubules were acquired on a LSM710 confocal scanning microscope (X20 objective), using automated multi-position scan. After stitching, tiled images of individual pairs of tubules were analyzed with IMARIS 8.0 to quantify the number of GFP-positive cells. Data of at least three independent experiments (approx. 20 tubules) were analyzed with GraphPad Prims 5, using two-tailed Mann-Whitney tests. The statistical significance of differences observed between compared genotypes was indicated as: *** (p<0.001), ns (p>0.05). Close-up pictures were

acquired using Leica SPE and Leica SP8 confocal laser scanning microscopes (X40 and X63 objectives). Laser intensity and background filtering was set according to the control samples and remained the same for all subsequent samples. The intensity of most pictures has been enhanced equally for all images within the same experiment using adjustments in Photoshop CS5. All images were processed using Adobe Photoshop, Illustrator CS5 and Inkscape 0.91.

Western blotting and immunoprecipitation. *Drosophila* S2 cells were grown in Schneider medium supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (Invitrogen) at 25°C. We used stable cell lines co-expressing the copper-inducible constructs pMT-Svb::GFP and pMT-pri¹⁷. S2 cell lines were cultured in six-well plates (1.75x10⁶ cells/3ml) and transfected in 100 µl of Opti-MEM (Invitrogen) with 3 µl of EugeneHD (Promega) and the indicated constructs. CuSO₄ (final concentration of 1mM) was used to induce the expression of pMT plasmids. The following plasmids were used: pAc-Yki::HA and its related mutated version pAc-Yki-WW::HA. Cells were lysed in 250 µl of ice-cold lysis buffer (150 mM NaCl, 50mM Tris [pH 8], 0.5% NP40, 1mM EGTA, 0.5M NaF, 200mM vanadate, phosphatase inhibitor cocktail 1 (Sigma) and protease inhibitors (Roche). After clearing by centrifugation at 14,000 rpm for 10 min, immuno-precipitations were done from transfected lysates in lysis buffer using anti-GFP antibody (GFP-trap, Chromotek). Immuno-precipitated samples were separated by SDS-PAGE and transferred to PVDF membranes, then blotted using anti-GFP (TP401, Acris Antibodies, 1:10000) and anti-HA (Covance, 1:2.000) antibodies. Secondary antibodies anti-mouse or anti-rabbit IgG-HRP conjugates (Jackson Laboratory, 1:10.000) were detected using ECL Clarity (Biorad).

Northern blot analysis. Using adult total RNAs as a starting material, DNA fragments containing coding sequence of *yki*, *CycE* and *DIAP1* were reverse transcribed and PCR-amplified with pairs of specific primers: CTGCC CAACT CCTTC TTCAC (forward) and

387 AACTG AATGG GGCTG ATGAC (reverse) for *yki*; GATGA CGTTG AGGAG GAGGA
388 (forward) and TGCCT CTTCT GCACC TTATG (reverse) for *CycE*; CCGAG GAACC
389 TGAAA CAGAA (forward) and GCACA ACTTT TCCTC GGGTA (reverse) for *DIAP1*. A
390 SP6 promoter sequence (CAAGC TATTT AGGTG AACT ATAG) was attached to each
391 reverse primer for *in vitro* transcription. DIG-labelled probes were prepared with SP6 RNA
392 polymerase, according to the supplier's manual (Roche). Northern blot analysis was described
393 previously¹⁸. Briefly, 2 days-old adults were frozen with liquid nitrogen and heads were
394 sorted with sieves, followed by RNA purification with Isogen (Nippon Gene). 1 µg of RNA
395 *per* lane was separated by formaldehyde–agarose gel electrophoresis and then transferred to a
396 nylon membrane (Roche). Hybridization and wash procedures were carried out at 52°C and
397 65°C, respectively. The filters were reacted with an alkaline phosphatase-conjugated anti-DIG
398 antibody (Roche) and chemiluminescent reactions with CPD-Star (Roche) were detected by
399 LAS 4000mini (GE Healthcare).

Genotypes

Figure 1A: *yw/w; esg-Gal4, UAS-GFP/ tsh-LacZ*

Figure 1B: *yw/w; esg-LacZ/+; svb^{E3N}-GFP/+*

Figure 1C&D control: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/+*

Figure 1C&D svb-RNAi: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-svb-RNAi*

Figure 1E control: *yw, hsFLP, tubulin-Gal80 FR19A; UAS-mCD8::GFP/+; tubulin-Gal4/ry⁵⁰⁶*

Figure 1E svb^{R9}: *yw, hsFLP, tubulin-Gal80 FR19A/ yw svb^{R9} FRT19A; UAS-mCD8::GFP/+; tubulin-Gal4/+*

Figure 2B: *tal-Gal4/ UAS-HB2::RFP*

Figure 2C control: *yw, hsFLP, tubulin-Gal80 FR19A; UAS-mCD8::GFP/+; tubulin-Gal4/ry⁵⁰⁶*

Figure 2C ubr3^B: *yw, hsFLP, tubulin-Gal80 FR19A/ yw ubr3^B FRT19A; UAS-mCD8::GFP/+; tubulin-Gal4/+*

Figure 2D control: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/+*

Figure 2D svb-RNAi: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-svb-RNAi*

Figure 2D ovoA: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-ovoA*

Figure 2D ovoB: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-ovoB*

Figure 2D pri-RNAi: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-pri-RNAi*

Figure 2D EcRDN: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-EcRDN^{B2w650A}*

Figure 2D ubr3-RNAi: *yw/w; esg-Gal4, UAS-GFP/ UAS-ubr3 RNAi; tubulin-Gal80^{ts}/+*

Figure 2D ubr3-RNAi + ovoB: *yw/w; esg-Gal4, UAS-GFP/ ubr3 RNAi; tubulin-Gal80^{ts}/ UAS-ovoB/+*

Figure 3A control: *yw/w; esg-Gal4, UAS-mCD8::GFP/+; UAS-H2B::RFP, tubulin-Gal80^{ts}/+*

Figure 3A mir8: *yw/w, UAS-mir8; esg-Gal4, UAS-mCD8::GFP/+; UAS-H2B::RFP, tubulin-Gal80^{ts}/+*

Figure 3A svb-RNAi: *yw/w ; esg-Gal4, UAS-mCD8::GFP/+; UAS-H2B::RFP, tubulin-Gal80^{ts}/ UAS-svb RNAi*

Figure 3B control: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/+*

Figure 3B svb-RNAi: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-svb-RNAi*

Figure 3C control: *yw/; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/+*

Figure 3C p35: *yw/; esg-Gal4, UAS-GFP/ UAS-p35; tubulin-Gal80^{ts}/+*

Figure 3C svb-RNAi: *yw/; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-svb-RNAi*

Figure 3C p35+ svb-RNAi: *yw/; esg-Gal4, UAS-GFP/ UAS-p35; tubulin-Gal80^{ts}/ UAS-svb-RNAi*

Figure 4A control: *yw/; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/+*

Figure 4A hpo: *yw/; esg-Gal4, UAS-GFP/ UAS-hpo; tubulin-Gal80^{ts}/+*

Figure 4A yki: *yw/; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-yki*

Figure 4A DIAP1: *yw/; esg-Gal4, UAS-GFP/ +; tubulin-Gal80^{ts}/ UAS-DIAP1*

Figure 4A svb-RNAi: *yw/; esg-Gal4, UAS-GFP/ +; tubulin-Gal80^{ts}/ UAS-svb-RNAi*

Figure 4A hpo+ ovoBt: *yw/; esg-Gal4, UAS-GFP/ UAS-hpo; tubulin-Gal80^{ts}/ UAS-ovoB*

Figure 4A yki+ svb-RNAi: *yw/; esg-Gal4, UAS-GFP/ +; tubulin-Gal80^{ts}/ UAS-ovoB, UAS-yki*

Figure 4A DIAP1+ svb-RNAi: *yw/; esg-Gal4, UAS-GFP/ +; tubulin-Gal80^{ts}/ UAS-DIAP1, UAS-svb-RNAi*

Figure 4D control: *yw/; esg-Gal4, UAS-GFP/ +; tubulin-Gal80^{ts}/ DIAP1-LacZ/+*

Figure 4D yki: *yw/; esg-Gal4, UAS-GFP/ +; tubulin-Gal80^{ts}/ DIAP1-LacZ/ UAS-yki*

Figure 4D ovoA: *yw/; esg-Gal4, UAS-GFP/ +; tubulin-Gal80^{ts}/ DIAP1-LacZ/ UAS-ovoA*

447 **Figure 4D** *yki + ovoA*: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/DIAP1-LacZ/ UAS-yki,*
448 *UAS-ovoA*
449 **Figure 4E control**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/DIAP14.3-GFP/+*
450 **Figure 4E yki**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/DIAP14.3-GFP/ UAS-yki*
451 **Figure 4E ovoA**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/DIAP14.3-GFP/ UAS-ovoA*
452 **Figure 4E yki + ovoA**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/DIAP14.3-GFP/ UAS-*
453 *yki, UAS-ovoA*

454 **Figure Sup1B**: *yw/w; esg-LacZ/svb^{E10}-GFP*
455 **Figure Sup1C**: *yw/w; esg-LacZ/+*
456 **Figure Sup1C**: *w; svb^{E3N}-LacZ/+*
457 **Figure Sup1C**: *w; svb^{E6}-LacZ/+*
458 **Figure Sup1D**: *yw/w; esg-Gal4, UAS-GFP/+*
459 **Figure Sup1E control**: *yw/w; dome-meso-Gal4, UAS-mCherry/+*
460 **Figure Sup1E svb-RNAi**: *yw/w; dome-meso-Gal4, UAS-mCherry/+; UAS-svb-RNAi/+*

461 **Figure Sup2B**: *yw/w; esg-LacZ/+*
462 **Figure Sup2B**: *w; priA-LacZ/+*
463 **Figure Sup2B**: *yw/+; priJ-LacZ/+*

464 **Figure Sup3A**: *yw/w; esg-Gal4, UAS-GFP/+*
465 **Figure Sup3B control**: *yw/w; esg-Gal4, UAS-mCD8::GFP/+; UAS-H2B::RFP, tubulin-*
466 *Gal80^{ts}/+*
467 **Figure Sup3B miR-8**: *yw/UAS-mir8; esg-Gal4, UAS-mCD8::GFP/+; UAS-H2B::RFP,*
468 *tubulin-Gal80^{ts}/+*
469 **Figure Sup3C control**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/+*
470 **Figure Sup3C ovoB**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/UAS-ovoB*
471 **Figure Sup3C yki-RNAi**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-yki*
472 **Figure Sup3C yki-RNAi + ovoB**: *yw/w; esg-Gal4, UAS-GFP/+; tubulin-Gal80^{ts}/ UAS-yki, UAS-*
473 *ovoB*
474 **Figure Sup3D ctrl**: *yw/w; col-Gal4, UAS-mCD8::GFP/+*
475 **Figure Sup3D yki-RNAi**: *yw/w; col-Gal4, UAS-mCD8::GFP/+; UAS-yki/+*
476 **Figure Sup3D ovoA**: *yw/w; col-Gal4, UAS-mCD8::GFP/+; UAS-ovoA/+*
477 **Figure Sup3D yki-RNAi + ovoA**: *yw/w; col-Gal4, UAS-mCD8::GFP/+; UAS-yki, UAS-*
478 *ovoA/+*
479 **Figure Sup3E ctrl**: *yw/w; GMR-Gal4/+*
480 **Figure Sup3E pri**: *yw/w; GMR-Gal4/UAS-pri*
481 **Figure Sup3E yki**: *yw/w; GMR-Gal4/+; UAS-yki*
482 **Figure Sup3E pri+ yki**: *yw/w; GMR-Gal4/UAS-pri; UAS-yki/+*

References

1. Kumar, A. *et al.* Molecular phylogeny of OVOL genes illustrates a conserved C2H2 zinc finger domain coupled by hypervariable unstructured regions. *PLoS One* **7**, e39399 (2012).
2. Mevel-Ninio, M., Terracol, R., Salles, C., Vincent, A. & Payre, F. ovo, a Drosophila gene required for ovarian development, is specifically expressed in the germline and shares most of its coding sequences with shavenbaby, a gene involved in embryo patterning. *Mech Dev* **49**, 83-95 (1995).
3. Payre, F., Vincent, A. & Carreno, S. ovo/svb integrates Wingless and DER pathways to control epidermis differentiation. *Nature* **400**, 271-275 (1999).
4. Dai, X. *et al.* The ovo gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice. *Genes Dev* **12**, 3452-3463 (1998).
5. Li, B. *et al.* Ovol1 regulates meiotic pachytene progression during spermatogenesis by repressing Id2 expression. *Development* **132**, 1463-1473 (2005).
6. Wells, J. *et al.* Ovol2 suppresses cell cycling and terminal differentiation of keratinocytes by directly repressing c-Myc and Notch1. *J Biol Chem* **284**, 29125-29135 (2009).
7. Crocker, J. *et al.* Low affinity binding site clusters confer hox specificity and regulatory robustness. *Cell* **160**, 191-203 (2015).
8. Frankel, N. *et al.* Phenotypic robustness conferred by apparently redundant transcriptional enhancers. *Nature* **466**, 490-493 (2010).
9. Frankel, N. *et al.* Morphological evolution caused by many subtle-effect substitutions in regulatory DNA. *Nature* **474**, 598-603 (2011).
10. McGregor, A.P. *et al.* Morphological evolution through multiple cis-regulatory mutations at a single gene. *Nature* **448**, 587-590 (2007).
11. Sucena, E., Delon, I., Jones, I., Payre, F. & Stern, D.L. Regulatory evolution of shavenbaby/ovo underlies multiple cases of morphological parallelism. *Nature* **424**, 935-938 (2003).
12. Chanut-Delalande, H., Fernandes, I., Roch, F., Payre, F. & Plaza, S. Shavenbaby couples patterning to epidermal cell shape control. *PLoS Biol* **4**, e290 (2006).
13. Fernandes, I. *et al.* Zona pellucida domain proteins remodel the apical compartment for localized cell shape changes. *Dev Cell* **18**, 64-76 (2010).
14. Menoret, D. *et al.* Genome-wide analyses of Shavenbaby target genes reveals distinct features of enhancer organization. *Genome Biol* **14**, R86 (2013).
15. Chanut-Delalande, H., Ferrer, P., Payre, F. & Plaza, S. Effectors of tridimensional cell morphogenesis and their evolution. *Semin Cell Dev Biol* **23**, 341-349 (2012).
16. Zanet, J., Chanut-Delalande, H., Plaza, S. & Payre, F. Small Peptides as Newcomers in the Control of Drosophila Development. *Curr Top Dev Biol* **117**, 199-219 (2016).
17. Kondo, T. *et al.* Small peptides switch the transcriptional activity of Shavenbaby during Drosophila embryogenesis. *Science* **329**, 336-339 (2010).
18. Chanut-Delalande, H. *et al.* Pri peptides are mediators of ecdysone for the temporal control of development. *Nat Cell Biol* **16**, 1035-1044 (2014).
19. Watanabe, K. *et al.* Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. *Dev Cell* **29**, 59-74 (2014).

- 523 20. Roca, H. *et al.* A bioinformatics approach reveals novel interactions of the OVOL transcription factors in
524 the regulation of epithelial - mesenchymal cell reprogramming and cancer progression. *BMC Syst Biol* **8**,
525 29 (2014).
- 526 21. Hong, T. *et al.* An Ovol2-Zeb1 Mutual Inhibitory Circuit Governs Bidirectional and Multi-step Transition
527 between Epithelial and Mesenchymal States. *PLoS Comput Biol* **11**, e1004569 (2015).
- 528 22. Roca, H. *et al.* Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition
529 in human cancer. *PLoS One* **8**, e76773 (2013).
- 530 23. Wang, Z.H. *et al.* Ovol2 gene inhibits the Epithelial-to-Mesenchymal Transition in lung adenocarcinoma
531 by transcriptionally repressing Twist1. *Gene* **600**, 1-8 (2017).
- 532 24. Ricketts, C.J. *et al.* Genome-wide CpG island methylation analysis implicates novel genes in the
533 pathogenesis of renal cell carcinoma. *Epigenetics* **7**, 278-290 (2012).
- 534 25. Jia, D. *et al.* OVOL guides the epithelial-hybrid-mesenchymal transition. *Oncotarget* **6**, 15436-15448
535 (2015).
- 536 26. Li, S. & Yang, J. Ovol proteins: guardians against EMT during epithelial differentiation. *Dev Cell* **29**, 1-2
537 (2014).
- 538 27. Nieto, M.A., Huang, R.Y., Jackson, R.A. & Thiery, J.P. Emt: 2016. *Cell* **166**, 21-45 (2016).
- 539 28. Jolly, M.K. *et al.* Coupling the modules of EMT and stemness: A tunable 'stemness window' model.
540 *Oncotarget* **6**, 25161-25174 (2015).
- 541 29. Wu, R.S. *et al.* OVOL2 antagonizes TGF-beta signaling to regulate epithelial to mesenchymal transition
542 during mammary tumor metastasis. *Oncotarget* **8**, 39401-39416 (2017).
- 543 30. Lapan, S.W. & Reddien, P.W. Transcriptome analysis of the planarian eye identifies ovo as a specific
544 regulator of eye regeneration. *Cell Rep* **2**, 294-307 (2012).
- 545 31. Lee, B. *et al.* Transcriptional mechanisms link epithelial plasticity to adhesion and differentiation of
546 epidermal progenitor cells. *Dev Cell* **29**, 47-58 (2014).
- 547 32. Kitazawa, K. *et al.* OVOL2 Maintains the Transcriptional Program of Human Corneal Epithelium by
548 Suppressing Epithelial-to-Mesenchymal Transition. *Cell Rep* **15**, 1359-1368 (2016).
- 549 33. Kim, J.Y. *et al.* OVOL2 is a critical regulator of ER71/ETV2 in generating FLK1+, hematopoietic, and
550 endothelial cells from embryonic stem cells. *Blood* **124**, 2948-2952 (2014).
- 551 34. Beyenbach, K.W., Skaer, H. & Dow, J.A. The developmental, molecular, and transport biology of
552 Malpighian tubules. *Annu Rev Entomol* **55**, 351-374 (2010).
- 553 35. Denholm, B. Shaping up for action: the path to physiological maturation in the renal tubules of *Drosophila*.
554 *Organogenesis* **9**, 40-54 (2013).
- 555 36. Sözen, M.A., Armstrong, J.D., Yang, M., Kaiser, K. & Dow, J.A. Functional domains are specified to
556 single-cell resolution in a *Drosophila* epithelium. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 5207-5212 (1997).
- 557 37. Singh, S.R., Liu, W. & Hou, S.X. The adult *Drosophila* malpighian tubules are maintained by multipotent
558 stem cells. *Cell Stem Cell* **1**, 191-203 (2007).
- 559 38. Takashima, S., Paul, M., Aghajanian, P., Younossi-Hartenstein, A. & Hartenstein, V. Migration of
560 *Drosophila* intestinal stem cells across organ boundaries. *Development* **140**, 1903-1911 (2013).
- 561 39. Micchelli, C.A. & Perrimon, N. Evidence that stem cells reside in the adult *Drosophila* midgut epithelium.
562 *Nature* **439**, 475-479 (2006).

- 563 40. Loza-Coll, M.A., Southall, T.D., Sandall, S.L., Brand, A.H. & Jones, D.L. Regulation of *Drosophila*
564 intestinal stem cell maintenance and differentiation by the transcription factor Escargot. *EMBO J* **33**, 2983-
565 2996 (2014).
- 566 41. Korzelius, J. *et al.* Escargot maintains stemness and suppresses differentiation in *Drosophila* intestinal stem
567 cells. *EMBO J* **33**, 2967-2982 (2014).
- 568 42. Stern, D.L. & Frankel, N. The structure and evolution of cis-regulatory regions: the shavenbaby story.
569 *Philos. Trans. R. Soc. Lond., B, Biol. Sci.* **368**, 20130028 (2013).
- 570 43. Jiang, H. *et al.* Cytokine/Jak/Stat Signaling Mediates Regeneration and Homeostasis in the *Drosophila*
571 Midgut. *Cell* **137**, 1343-1355 (2009).
- 572 44. Delon, I., Chanut-Delalande, H. & Payre, F. The Ovo/Shavenbaby transcription factor specifies actin
573 remodelling during epidermal differentiation in *Drosophila*. *Mech Dev* **120**, 747-758 (2003).
- 574 45. Zanet, J. *et al.* Pri sORF peptides induce selective proteasome-mediated protein processing. *Science* **349**,
575 1356-1358 (2015).
- 576 46. Galindo, M.I., Pueyo, J.I., Fouix, S., Bishop, S.A. & Couso, J.P. Peptides encoded by short ORFs control
577 development and define a new eukaryotic gene family. *PLoS Biol* **5**, e106 (2007).
- 578 47. Andrews, J. *et al.* OVO transcription factors function antagonistically in the *Drosophila* female germline.
579 *Development* **127**, 881-892 (2000).
- 580 48. Antonello, Z.A., Reiff, T., Esther, B.-I. & Dominguez, M. Robust intestinal homeostasis relies on cellular
581 plasticity in enteroblasts mediated by *miR-8-Escargot* switch. *EMBO J.* **34**, 2025-2041 (2015).
- 582 49. Yang, M.Y., Wang, Z., MacPherson, M., Dow, J.A. & Kaiser, K. A novel *Drosophila* alkaline phosphatase
583 specific to the ellipsoid body of the adult brain and the lower Malpighian (renal) tubule. *Genetics* **154**, 285-
584 297 (2000).
- 585 50. Ma, M. *et al.* Wildtype adult stem cells, unlike tumor cells, are resistant to cellular damages in *Drosophila*.
586 *Dev Biol* **411**, 207-216 (2016).
- 587 51. Hay, B.A., Wolff, T. & Rubin, G.M. Expression of baculovirus P35 prevents cell death in *Drosophila*.
588 *Development* **120**, 2121-2129 (1994).
- 589 52. Payre, F. Genetic control of epidermis differentiation in *Drosophila*. *Int J Dev Biol* **48**, 207-215 (2004).
- 590 53. Pan, D. The hippo signaling pathway in development and cancer. *Dev. Cell* **19**, 491-505 (2010).
- 591 54. Staley, B.K. & Irvine, K.D. Hippo signaling in *Drosophila*: recent advances and insights. *Dev. Dyn.* **241**,
592 3-15 (2012).
- 593 55. Sansores-Garcia, L. *et al.* Modulating F-actin organization induces organ growth by affecting the Hippo
594 pathway. *EMBO J* **30**, 2325-2335 (2011).
- 595 56. Gaspar, P., Holder, M.V., Aerne, B.L., Janody, F. & Tapon, N. Zyxin antagonizes the FERM protein
596 expanded to couple f-actin and yorkie-dependent organ growth. *Current Biology* **25**, 679-689 (2015).
- 597 57. Shaw, R.L. *et al.* The Hippo pathway regulates intestinal stem cell proliferation during *Drosophila* adult
598 midgut regeneration. *Development* **137**, 4147-4158 (2010).
- 599 58. Staley, B.K. & Irvine, K.D. Warts and yorkie mediate intestinal regeneration by influencing stem cell
600 proliferation. *Current Biology* **20**, 1580-1587 (2010).
- 601 59. Oh, H. & Irvine, K.D. Cooperative regulation of growth by Yorkie and Mad through bantam. *Dev Cell* **20**,
602 109-122 (2011).

60. Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. *Cell* **122**, 421-434 (2005).
61. Zhang, X., Milton, C.C., Poon, C.L., Hong, W. & Harvey, K.F. Wbp2 cooperates with Yorkie to drive tissue growth downstream of the *Salvador-Warts-Hippo* pathway. *Cell Death Differ.* **18**, 1346-1355 (2011).
62. Oh, H. *et al.* Genome-wide association of Yorkie with chromatin and chromatin-remodeling complexes. *Cell Rep* **3**, 309-318 (2013).
63. Zhang, C. *et al.* The ecdysone receptor coactivator Taiman links Yorkie to transcriptional control of germline stem cell factors in somatic tissue. *Dev Cell* **34**, 168-180 (2015).
64. Poernbacher, I., Baumgartner, R., Marada, S.K., Edwards, K. & Stocker, H. Drosophila *Pez* acts in Hippo signaling to restrict intestinal stem cell proliferation. *Curr Biol* **22**, 389-396 (2012).
65. Tapon, N. *et al.* *salvador* Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. *Cell* **110**, 467-478 (2002).
66. Payre, F. & Desplan, C. RNA. Small peptides control heart activity. *Science* **351**, 226-227 (2016).
67. Pueyo, J.I., Magny, E.G. & Couso, J.P. New Peptides Under the s(ORF)ace of the Genome. *Trends Biochem Sci* **41**, 665-678 (2016).
68. Karpowicz, P., Perez, J. & Perrimon, N. The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration. *Development* **137**, 4135-4145 (2010).
69. Huang, Q. *et al.* Ubr3 E3 ligase regulates apoptosis by controlling the activity of DIAP1 in Drosophila. *Cell Death Differ* **21**, 1961-1970 (2014).
70. Tang, Y., Feinberg, T., Keller, E.T., Li, X.Y. & Weiss, S.J. Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation. *Nat Cell Biol* **18**, 917-929 (2016).

Acknowledgments


We are grateful to FlyBase, Bloomington and Vienna stock centers, Developmental Studies Hybridoma Bank, as well as N. Tapon, J. Colombani, K.F. Harvey, D.J. Pan, J. Dow and H. Skaer and M. Crozatier, for providing flies, antibodies and molecular reagents. We also thank B. Ronsin (Toulouse RIO Imaging) for help with microscopy, A. Alsawadi, A. Dib, J. Zanet, M. Soulard and P. Valenti for experimental support. We also thank all members of the Payre lab for critical reading of the manuscript. This work was supported by ANR (Chrononet), Fondation pour la Recherche Médicale (FRM), Programme Scientifique de Coopération Internationale (PSCI) for D.O. and F.P., and by MEXT KAKENHI (JP26113006) for Y.K.. J.B. was supported by fellowships from “Ministère de l’Enseignement et de la Recherche” and “La Ligue contre le Cancer.”

Author Contributions

C.P., S.P., Y.K., D.O. and F.P. conceived and directed the project, following initial observations made by D.O.. J.B. carried out most of the experiments presented here, under the supervision of C.P. and other experiments were conducted by C.P., K.A., Y.Y, S.I and D.O.. A.M.F analyzed NGS data. J.B., C.P., K.A., Y.Y., S.I., H.C.D., S.P., Y.K., D.O. and F.P. analyzed data and contributed to their interpretation. J.B., C.P. and F.P. prepared the figures and wrote the manuscript. All authors helped to write the paper.


Competing financial interests.

The authors declare having not competing financial interests.




Bohère et al., Figure 1

Figure 1: *svb* is expressed in RNSCs and required for their maintenance. (a) Adult Malpighian tubules are composed of three types of cells. Principal cells (PC) are identified by immunostaining against Cut (cyan) and stellate cells (SC) by *tsh-LacZ* (in red). RNSCs located in the lower tubules express *esg-Gal4*, *UAS-GFP* (green). (b) Fork region of the Malpighian tubules. The expression of *svb* and *esg* was monitored by the expression of *svb-E-GFP* (green) and *esg-LacZ* (red) enhancers, respectively. Nuclei were stained with DAPI (blue). (c) *esg^{ts}*-driven *svb-RNAi* leads to a progressive decrease in the number of RNSCs compared to control conditions (*esg^{ts}* driving only GFP). (d) Quantification of the number of RNSCs (*esg-GFP* positive) after 4, 8, 16 and 32 of transgene induction in control (green) and *svb-RNAi* (red) conditions. (e) Genetic mosaics (MARCM) showing control and *svb^{R9}* clones, positively labelled with GFP (green) in the fork region of Malpighian tubules, 25 days after clone induction. The white arrowhead indicates the position of a *svb*-mutant cell.




Bohère et al., Figure 2

Figure 2: Processing of Svb is essential for RNSC maintenance. (a) Schematic representation of Svb maturation, as well as the germinal isoforms OvoA and OvoB that act as constitutive (*pri*-independent) repressor and activator, respectively. (b) Expression of *pri* monitored by the activity of *pri-Gal4* driving the expression of H2B::RFP (red). The nuclei (DAPI) are in blue. (c) MARCM clones of control and *ubr3^B* cells, 25 days after induction. Arrowheads indicate positions of *ubr3* mutant cells. (d) Fork region of Malpighian tubules, with *esg^{ts}*-driven expression of GFP and the indicated transgenes, after 8 days of induction. Quantification of the number of *esg*⁺ cells per tubule is indicated on the right of each picture (see also Supplementary Figure 2).



Bohère et al., Figure 3

Figure 3: *svb* protects RNSCs from apoptosis. (a) Lineage-tracing experiments (*esg-ReDDM*) at 8 days after induction. While RNSCs express both mCD8::GFP (green) and H2B::RFP (red), only the stable H2B::RFP protein persists in their progeny. Nuclei are in blue (DAPI). RFP positive cells that lack or display remnants of GFP levels are indicated by arrows and arrowheads, respectively. (b) Left, three-dimensional reconstruction of 3 different RNSCs in *control* (*esg^{ts}>GFP*) and *svb-RNAi* contexts. Pictures show GFP after 8 days of treatment. Right, quantification of the RNSC volume in *control* (*Ctrl*, green) and *svb-RNAi* conditions. (c) Rescue of *svb*-depleted RNSCs by *p35*. *esg^{ts}* was used to drive the expression of indicated transgenes (together with GFP), during 8 days. Quantification of *esg^{ts}* cells is shown at the right of each picture.



Bohère *et al.*, Figure 4

Figure 4: *svb* is a member of the Hippo pathway. (a) Pictures of Malpighian tubules with *esg^{ts}*-driven expression of GFP (control) and indicated transgenes. Quantification of *esg*⁺ cells is given on each picture (see also Supplementary Figure 3f). (b) Drawing of the *DIAP1* locus. Exons are represented in cyan, the *DIAP1-4.3* enhancer in dark green and the insertion site of the *DIAP1-LacZ* reporter (J5C8) is in red. Regions bound in ChIP-seq (MACS peaks) by Svb and Yki are indicated in green and magenta, respectively. (c) Svb co-immuno-precipitates with Yki in S2 cells. Svb::GFP and Yki::HA, or a mutated form of Yki substituting the WW domains (YkiWW::HA), were expressed in S2 cells. Protein immuno-precipitated by anti-GFP were blotted with anti-GFP and anti-HA antibodies. (d) *esg^{ts}* was used to drive the expression of *yki*, *svb^{REP}* (*ovoA*), and *yki* together with *svb^{REP}* in RNSCs. The expression of *DIAP1* was followed by the activity of *DIAP1-lacZ*. (e) Expression of the *DIAP1-4.3-GFP* enhancer was followed by immuno-staining against GFP (green) and Hindsight (Hnt, red) revealing the antagonistic influence of Yki and OvoA on RNSCs.